Primary chemotherapy versus primary surgery for ovarian cancer

摘要

Sean Kehoe and colleagues (July 18, p 249) recently reported the results of the CHORUS trial and concluded that survival in women with advanced ovarian cancer receiving primary chemotherapy is non-inferior to primary debulking surgery.However, the authors reported an optimal cytoreduction rate of 41% in the primary debulking surgery group, with a median overall survival of 22-6 months, which istowardsthe lower limit of overall survival according to the scientific literature; but considering that residual disease after surgery remains the most important prognostic factor of survival, we believe the low median overall survival could represent a fundamental bias that would affect the proper interpretation of data.